TP53 and B-cell chronic lymphocytic leukemia: Albeit, even with novel therapies the adverse prognostic impact of TP53-alterations, unmutated IGHV status and karyotype complexity still remains to be fully compensated, predisposing most CLL patients to multiple lines of therapy in the long run.